Journal of Crohn's & colitis
Cure8 research brief
Why This Matters
Patients and clinicians often wonder whether starting advanced therapies earlier after diagnosis affects how long patients stay on those drugs. This study suggests early use is common and may be associated with better persistence, which could influence treatment planning and discussions about early escalation.
Who Should Pay Attention
Newly diagnosed adults with Crohn's disease, patients considering or already on biologic/targeted therapies, gastroenterologists, and researchers studying early intervention strategies in IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The report enrolled patients aged ≥16 with newly diagnosed Crohn's disease who were advanced-therapy–naïve and followed real-world treatment choices. Of 672 patients, 498 (74%) started an advanced therapy; 60% began treatment within one year of diagnosis.
Three-year persistence estimates were: infliximab ~77.5%, adalimumab ~75.7%, ustekinumab ~79.8%, and vedolizumab ~49.0%. The authors used Kaplan–Meier and multivariable Cox models, and compared early versus delayed initiation using propensity score weighting.
Early initiation tended toward greater persistence versus delayed start (hazard ratio 0.61) but did not reach conventional statistical significance (P = .067). The registry is prospectively registered (UMIN000032237) and this entry reports an interim analysis of real-world treatment patterns and persistence.
Keep In Mind
This is an interim analysis from a registry (abstract-level content). Results are observational and reflect real-world prescribing and persistence; they do not establish causality. The early-versus-delayed comparison was adjusted but did not reach statistical significance, and the authors recommend confirmation in other prospective studies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of Crohn's & colitis
AuthorsShinichiro Shinzaki, Katsuyoshi Matsuoka, Toshimitsu Fujii +25 more
InstitutionDepartment of Gastroenterology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo, 663-8501, Japan.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedNov 7, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis.
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...